Former Omnyx CEO Gene Cartwright Joins Guided Therapeutics

| January 7, 2014

GTwithTag-R-99Norcross, GA.– (BUSINESS WIRE) — Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), the maker of the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly at the point of care, today announced the appointment of Gene Cartwright, 59, as Chief Executive Officer, effective January 6, 2014. Mr. Cartwright replaces Mark L. Faupel, who has transitioned to the role of Chief Scientific Officer.

“Gene has great experience in the diagnostics market both in the development and introduction of new diagnostics technologies as well as extensive successful commercial experience with global businesses,” said Michael James, Chairman of the Board of Directors for Guided Therapeutics. “The company is poised for accelerated growth and we are confident that Gene is the right person to move the company forward.”

Gene brings over 30 years of experience working in the IVD diagnostics industry. He joins Guided Therapeutics from Omnyx, LLC, a Joint Venture between GE Healthcare and the University of Pittsburgh Medical Center, where, as CEO for over four years he founded and managed the successful development of products for the field of Digital Pathology.

Prior to his work with Omnyx, LLC, he was President of Molecular Diagnostics for GE Healthcare. Prior to GE, he was Divisional Vice President/General Manager for Abbott Diagnostics’ Molecular Diagnostics business. In his 24 year career at Abbott, he also served as Divisional Vice President for U.S. Marketing for five years.

“I’m very excited to join Guided Therapeutics at this critical stage in the company’s history,” Mr. Cartwright said. “They have introduced their CE Marked LuViva product internationally and I look forward to growing the sales for this important new global product in the cervical cancer diagnostics market. I also will work diligently to achieve FDA approval for LuViva in the U.S. and build on the great work that has been done to date by Mark Faupel and the Guided Therapeutics team.”

He received a Masters of Management degree from Northwestern’s Kellogg School of Management and also holds a Ph.D. in chemistry from Stanford University and an AB from Dartmouth College.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva(R) Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. Guided Therapeutics is also developing a non-invasive test for the early detection of esophageal cancer using the technology platform. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva(R) Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use. LuViva, the wave logo and “Early detection, better outcomes” are registered trademarks owned by Guided Therapeutics, Inc.

Category: Clinical Laboratories, General Healthcare News, Pathology News, Vendor products

Comments are closed.